Stay updated with breaking news from Tolerability Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Imugene Ltd (ASX:IMU, OTC:IUGNF) has received Human Research Ethics Committee (HREC) approval to kick off an Australian Phase 1 clinical trial of its...
ND0612, a continuous 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the...
Imugene has now crossed ethics approval off is list, and the way is now clear for clinical trials to begin in Australia.
ND0612, a continuous 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without
Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.